A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3Through October more than 2,200 unique ...

Do cough, cold or other respiratory issues disrupt your sleep in the rising air pollution? Explore the best nebulizer ...

There is no cure for COPD, but it can be managed and treated by working with your healthcare team to develop a plan to keep your COPD under control. Along with quitting smoking, staying up to date ...

Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023- -NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Gangdong Kyunghee University Hospital (Director Lee Woo-in) won the first grade in the 9th COPD adequacy evaluation announced ...

Chronic Obstructive Pulmonary Disease (COPD): For those with COPD, exposure to pollutants can worsen symptoms ... Immediate ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Background: In contrast to asthma, the indication for bronchodilators prior to bronchoscopy in patients with COPD has not been properly investigated. We therefore performed a randomized ...

Current guidelines recommend use of one or more long-acting inhaled bronchodilators for patients with moderate, severe, or very severe COPD. However, the initial choice of long-acting inhaled ...